MYL : Summary for Mylan N.V. - Yahoo Finance

U.S. Markets closed

Mylan N.V. (MYL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
36.95-0.24 (-0.65%)
At close: 4:00PM EST

36.95 0.00 (0.00%)
After hours: 6:11PM EST

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close37.19
Bid36.70 x 200
Ask37.49 x 100
Day's Range36.71 - 37.30
52 Week Range33.60 - 54.23
Avg. Volume5,828,625
Market Cap19.77B
PE Ratio (TTM)74.05
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters3 hours ago

    EpiPen rival to be offered free to many but high price for insurers

    Privately held drugmaker Kaleo on Thursday said it would offer its Auvi-Q emergency allergy auto-injector at no cost to many consumers, but set a list price for the EpiPen rival that will be used as the benchmark cost to insurance companies at a whopping $4,500. EpiPen maker Mylan NV came under intense criticism last year when it raised the price for a pair of its life-saving auto-injectors to $600, putting it out of reach for many consumers. It has since said it will sell its own generic EpiPen for about half that price.

  • Reuters4 hours ago

    U.S. health agency tells Grassley there is no EpiPen deal yet

    Mylan NV has yet to reach a settlement with the U.S. Department of Justice over the classification in the Medicaid program of its life-saving EpiPen allergy treatment, according to a letter from a regulatory agency disclosed on Thursday. Mylan said in October that it would pay $465 million to resolve allegations it underpaid U.S. government healthcare programs.

  • EpiPen gets a new rival: Auvi-Q. Its pricing scheme will blow your mind
    CNBC5 hours ago

    EpiPen gets a new rival: Auvi-Q. Its pricing scheme will blow your mind

    Have allergies? This EpiPen rival has a list price of $4,500, but most patients won't pay a cent.